Tirzepatide (Mounjaro) has rapidly become one of the most discussed medications in diabetes and obesity medicine. Its dual GIP/GLP-1 receptor agonist mechanism produces unprecedented reductions in blood sugar and body weight. But what does the evidence say about its cardiovascular effects — and how does it compare to semaglutide?
How Tirzepatide Works
Unlike semaglutide, which acts on GLP-1 receptors alone, tirzepatide is a dual agonist — it activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. This dual mechanism produces synergistic effects on insulin secretion, glucagon suppression, gastric emptying, and appetite regulation, resulting in greater weight loss and blood sugar reduction than GLP-1 agonists alone.
The SURPASS Trial Programme: Blood Sugar and Weight Results
The SURPASS clinical trial programme, which evaluated tirzepatide across more than 6,000 participants with type 2 diabetes, produced remarkable results. At the highest dose (15mg weekly), tirzepatide reduced HbA1c by an average of 2.58% — the largest reduction ever seen with any glucose-lowering medication in a phase 3 trial. Body weight reductions of 11–15 kg were observed across the programme.
Cardiovascular Risk Factor Improvements
| Risk Factor | Change with Tirzepatide 15mg |
|---|---|
| Body weight | ↓ 11–15 kg (up to 22% in obesity trials) |
| Systolic blood pressure | ↓ 7–10 mmHg |
| Triglycerides | ↓ 24–28% |
| HDL cholesterol | ↑ 6–10% |
| Waist circumference | ↓ 10–14 cm |
The SURPASS-CVOT Trial: Definitive Cardiovascular Evidence
The dedicated cardiovascular outcomes trial for tirzepatide — SURPASS-CVOT — has been designed to determine whether tirzepatide reduces major adverse cardiovascular events (MACE: heart attack, stroke, cardiovascular death) in people with type 2 diabetes and established cardiovascular disease. Results are anticipated in 2025–2026 and are expected to confirm cardiovascular benefit based on the surrogate marker improvements already observed.
Tirzepatide produces the most impressive improvements in cardiovascular risk factors of any glucose-lowering medication to date — including dramatic reductions in weight, blood pressure, and triglycerides. While definitive cardiovascular outcomes data is pending, the evidence strongly suggests it will join semaglutide as a cardioprotective medication. If you have type 2 diabetes and significant cardiovascular risk, discuss tirzepatide with your diabetes team.
English 
Arabic 
Spanish 
Urdu